Santhera Plans to Announce Regulatory Feedback for Raxone® in DMD and 2017 Preliminary Key Financial Figures

Liestal, Switzerland, January 19, 2018 - Santhera Pharmaceuticals (SIX: SANN) expects to announce feedback from the CHMP on its Marketing Authorization Application (MAA) for Raxone® in Duchenne muscular dystrophy (DMD) on January 26, 2018, and will publish the Company's preliminary key financial figures for 2017 on January 29, 2018.

Announcement of CHMP opinion on MAA for Raxone® in DMD expected for January 26, 2018
Santhera expects to receive an opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its MAA filed as Type II extension application for Raxone® (idebenone) in DMD by January 26, following a re-examination procedure. Santhera expects to announce the CHMP opinion on January 26, 2018, at 07:00 hrs CET. On the same day, at 14:00 hrs CET, Thomas Meier, PhD, CEO of Santhera, will hold an investor conference call to discuss the outcome.

Announcement of 2017 Key Financials on January 29, 2018
Santhera will release its preliminary key financial figures for 2017 and provide a corporate update on January 29, 2018, at 07:00 hrs CET. In an investor conference call scheduled the same day at 14:00 hrs CET, Thomas Meier, PhD, CEO of Santhera, will discuss the key financials and the development of the business.

The 2017 Annual Report with full financial results will be published on March 20, 2018, at 07:00 hrs CET.

Access to conference calls
Participants can access either conference call by dialing one of the following numbers about 10 minutes before the call is due to start:
+41 (0)58 310 50 00 (Europe)
+44 (0)207 107 0613 (UK)
+1 (1)631 570 5613 (USA)